不适合顺铂的PD-L1阳性转移性或局部晚期尿路上皮癌患者的一线阿维鲁单抗治疗
ARIES试验筛查了198例不适合顺铂的转移性尿路上皮癌患者,其中PD-L1表达≥5%的71例(35.9%)入组接受一线阿维鲁单抗治疗。中位总生存期为10.0个月(95%CI 5.5-14.5个月),1年生存率为43%,完全缓解率8.5%,部分缓解率15.5%。任意级别和高级别不良事件发生率分别为49.3%和8.5%,仅1例3级输注反应为高级别治疗相关不良事件,无治疗相关死亡。
要点
- PD-L1表达≥5%的不适合顺铂转移性尿路上皮癌患者中,一线阿维鲁单抗中位OS为10.0个月。
- 1年生存率43%,完全缓解率8.5%,部分缓解率15.5%。
- 任意级别不良事件发生率49.3%,高级别8.5%,无治疗相关死亡。
核心结论
- ARIES试验证实阿维鲁单抗治疗转移性尿路上皮癌具有活性和安全性,为已批准用于铂类不适合的局部晚期/转移性尿路上皮癌的检查点抑制剂增加了新的治疗选择。
研究设计与样本
- ARIES试验为前瞻性研究,纳入不适合顺铂化疗的转移性尿路上皮癌患者,中心筛查PD-L1表达,仅肿瘤比例评分≥5%者入组。
- 共筛查198例患者,71例(35.9%)PD-L1表达≥5%并入组。
- 主要终点为1年总生存率,次要终点包括中位总生存期、中位无进展生存期、总缓解率、缓解持续时间、安全性和耐受性。
主要发现
- 中位年龄75岁,膀胱癌原发73.2%,肝转移25.3%。
- 顺铂不适合的主要原因包括肌酐清除率低(<60 ml/min)见于70.4%的患者,以及东部肿瘤协作组体能状态评分为2见于31%的患者。
- 中位总生存期为10.0个月(95%CI 5.5-14.5个月),1年时43%的患者存活。
- 完全缓解率8.5%,部分缓解率15.5%。
- 任意级别不良事件发生率49.3%,高级别不良事件发生率8.5%;3级输注反应是唯一的高级别治疗相关不良事件,未报告治疗相关死亡。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cisplatin-based chemotherapy is the most recommended treatment for metastatic urothelial cancer (mUC). However, about 50% of patients are considered to be cisplatin ineligible. Anti-programmed cell death protein 1/programmed death-ligand 1 (PD-L1) therapies have, nevertheless, increased the options available to clinicians and are especially valuable for treating these patients. This study therefore tested the activity and safety of avelumab as first-line therapy for mUC. PATIENTS AND METHODS: Patients with mUC who were ineligible for cisplatin-based chemotherapy were screened centrally for PD-L1 expression and only those with a tumour proportion score ≥ 5% were enrolled in the trial. The primary endpoint was 1-year overall survival (OS), and the secondary endpoints were median OS, median progression-free survival, overall response rate, duration of the response, safety and tolerability. All the survival rates were estimated with the Kaplan-Meier product-limit methodology and compared across groups using the log-rank test. RESULTS: A total of 198 patients were screened, with 71 (35.9%) whose PD-L1 expression was ≥5% enrolled in the study. The median age was 75 years, bladder cancer was the primary tumour in 73.2% of cases and 25.3% had liver metastases. The main reasons for the cisplatin ineligibility were a low rate of creatinine clearance (<60 ml/min), present in 70.4% of patients, and an Eastern Cooperative Oncology Group performance status of 2, which affected 31%. The median OS was 10.0 months (95% confidence interval 5.5-14.5 months) and 43% of patients were alive at 1 year. A complete response was achieved in 8.5% of cases, and 15.5% had a partial response. Adverse any-grade and high-grade events occurred in 49.3% and 8.5% of patients, respectively. A grade 3 infusion reaction was the only high-grade treatment-related adverse event. No treatment-related deaths were reported. CONCLUSIONS: This ARIES trial confirmed the activity and safety of avelumab for treating mUC, adding a new therapy option to the armamentarium of checkpoint inhibitors already approved for platinum-ineligible, locally advanced/mUC.
引用
- Iacovelli R, Ciccarese C, Brunelli M, et al. First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin. Ann Oncol. 2022. PMID: 35926813. doi:10.1016/j.annonc.2022.07.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。